ANI Pharmaceuticals Projects Rare Disease Revenues to Exceed $600 Million in 2026, Marking a Major Strategic Shift
Rare Disease Segment Poised to Represent 60% of All Revenues in 2026
ANI Pharmaceuticals (NASDAQ: ANIP) has set the stage for a transformative 2026, unveiling guidance that foresees its Rare Disease portfolio driving approximately 60% of total net revenues—up from just over 40% in 2025. Central to this momentum is Cortrophin Gel, which is expected to generate between $540 million and $575 million in net sales for 2026, a projected year-over-year increase of up to 65%. Together with ILUVIEN and YUTIQ, the company’s Rare Disease products are anticipated to generate over $600 million in sales, making them the key engine of ANI’s growth.
Strong Performance and Ambitious Targets Highlight Momentum
2025 proved pivotal for ANI, as the company delivered at least 39% growth in total net revenues and a minimum 42% increase in adjusted non-GAAP EBITDA. Rare Disease net revenues for 2025 tallied $347.8 million for Cortrophin Gel—a 76% surge year-over-year—and $74.9 million for ILUVIEN and YUTIQ combined, based on preliminary and unaudited results. This momentum sets a solid foundation for ANI’s ambitious 2026:
| Metric | 2026 Guidance | Year-over-Year Growth |
|---|---|---|
| Total Net Revenue | $1,055M – $1,115M | 24% – 28% |
| Cortrophin Gel Net Revenue | $540M – $575M | 55% – 65% |
| ILUVIEN Net Revenue | $78M – $83M | 4% – 11% |
| Adjusted Non-GAAP EBITDA | $275M – $290M | 24% – 27% |
| Adjusted Non-GAAP Diluted EPS | $8.83 – $9.34 | 20% – 22% |
Strategic Focus: Growth in Acute Gouty Arthritis and Rare Disease Leadership
ANI plans a ~90-person expansion of its Rare Disease organization by mid-2026, targeting the acute gouty arthritis flares indication—an area where Cortrophin Gel holds a unique market position. The company’s strategy includes advancing Phase 4 trials for Cortrophin Gel, broadening patient outreach, and leveraging commercial and access initiatives to sustain ILUVIEN’s growth.
Meanwhile, the Generics division will maintain its pace of 10–15 new annual launches, supporting diversified revenue streams and cash flow to fuel Rare Disease initiatives. Investment in R&D remains a priority, with a high single-digit percent of Generics revenue earmarked for pipeline expansion.
Financial Health Supports Expansion
As of year-end 2025, ANI reported roughly $285 million in cash and cash equivalents, providing ample flexibility to fund growth efforts, especially as Rare Disease becomes the cornerstone of its value proposition. For 2026, company-wide adjusted non-GAAP gross margin is guided between 59.3% and 60.3%—highlighting the blend of volume expansion and profitability improvements.
Key Takeaways for Investors
- ANI’s Rare Disease portfolio is projected to cross $600 million in revenue for 2026—making up the majority of company sales for the first time.
- Expansion into acute gouty arthritis and continued advancement in nephrology, neurology, and rheumatology underscore the company’s commitment to specialty therapeutics.
- Strong cash reserves and disciplined capital allocation put the company in a favorable position to capture additional opportunities in rare and specialty markets.
With ambitious revenue targets, a rapidly growing Rare Disease franchise, and organizational investments to capture unique market opportunities, ANI appears set to redefine its profile within the specialty pharmaceuticals landscape over the next year. The shift to Rare Disease leadership may continue to attract attention as these projections become reality—making ANI a company to watch in 2026.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI